Hypermarcas (OTCMKTS:HYPMY) Trading Up 9.3% - Should You Buy?

Key Points

• Hypermarcas shares increased by 9.3%, reaching $4.07 during trading on Monday.
• Scotiabank upgraded Hypermarcas to a "strong-buy" rating, contributing to its consensus rating of "Strong Buy".
• The company reported earnings of $0.12 per share for its last quarter, with a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares rose 9.3% during trading on Monday . The company traded as high as $4.07 and last traded at $4.07. Approximately 27,103 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 60,797 shares. The stock had previously closed at $3.72.

Analyst Upgrades and Downgrades

Separately, Scotiabank raised Hypermarcas to a "strong-buy" rating in a report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, Hypermarcas currently has a consensus rating of "Strong Buy".

Hypermarcas Price Performance

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of 19.62 and a beta of 0.83. The stock has a 50-day moving average price of $4.20 and a 200 day moving average price of $4.29.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share (EPS) for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.